Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9Y235
UPID:
ABEC2_HUMAN
Alternative names:
mRNA(cytosine(6666)) deaminase 2
Alternative UPACC:
Q9Y235; B2R899; Q53F28; Q5TGU5; Q5TGU6
Background:
C->U-editing enzyme APOBEC-2, also known as mRNA(cytosine(6666)) deaminase 2, is a probable C to U editing enzyme with a yet unidentified physiological substrate. It does not exhibit apoB mRNA editing but has a low intrinsic cytidine deaminase activity. This enzyme may play a crucial role in the epigenetic regulation of gene expression through active DNA demethylation.
Therapeutic significance:
Understanding the role of C->U-editing enzyme APOBEC-2 could open doors to potential therapeutic strategies.